CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
利用抗体药物偶联物(ADCs)和双特异性抗体(bsAbs)的工程方法旨在克服传统化疗和治疗性抗体的局限性,如耐药性和非特异性毒性。癌症免疫疗法已通过检查点阻断和CAR-T 细胞疗法显示出临床成功;然而,过度活跃的免疫系统仍是一个主要问题。鉴于肿瘤环境的复杂性,拥有针对两个或多个分子的策略将是有利的。
我们强调针对癌症的多靶点平台策略的必要性和重要性。目前约有400种ADCs和超过200种bsAbs正在针对多种适应症进行临床开发,并显示出有前景的治疗活性迹象。ADCs包括识别肿瘤抗原的抗体、稳定连接药物的连接子以及强效细胞毒性药物,也称为载荷。ADCs通过用强效载荷靶向癌症而具有直接治疗效果。另一类使用抗体的药物是bsAbs,通过连接抗原识别位点或桥接细胞毒性免疫细胞与肿瘤细胞来靶向两种抗原,从而实现癌症免疫治疗。2022年,FDA和EMA已批准三种bsAbs和一种ADC使用。其中,两种bsAbs和一种ADC用于癌症。
我们在本综述中介绍,bsADC,即ADC和bsAbs的组合,尚未获批,且几种候选药物处于临床开发的早期阶段。bsADCs技术有助于提高ADCs的特异性或bsAbs的内化和杀伤能力。
我们还简要讨论了点击化学在高效开发ADC和bsAb中作为偶联策略的应用。本综述总结了已获批用于抗癌或目前正在开发的ADC、bsAb和bsADC。这些策略可选择性地将药物递送至恶性肿瘤细胞,并可作为多种类型癌症的治疗方法。
Engineering approaches using antibody drug conjugates (ADCs) and bispecific antibodies (bsAbs) are designed to overcome the limitations of conventional chemotherapies and therapeutic antibodies such as drug resistance and non-specific toxicity.
Cancer immunotherapies have been shown to be clinically successful with checkpoint blockade and chimeric antigen receptor T cell therapy; however, overactive immune systems still represent a major problem. Given the complexity of a tumor environment, it would be advantageous to have a strategy targeting two or more molecules.
We highlight the necessity and importance of a multi-target platform strategy against cancer. Approximately 400 ADCs and over 200 bsAbs are currently being clinically developed for several indications, with promising signs of therapeutic activity. ADCs include antibodies that recognize tumor antigens, linkers that stably connect drugs, and powerful cytotoxic drugs, also known as payloads.
ADCs have direct therapeutic effects by targeting cancers with a strong payload. Another type of drug that uses antibodies are bsAbs, targeting two antigens by linking to antigen recognition sites or bridging cytotoxic immune cells to tumor cells, resulting in cancer immunotherapy. Three bsAbs and one ADC have been approved for use by the FDA and the EMA in 2022. Among these, two of the bsAbs and the one ADC are used for cancers.
We introduced that bsADC, a combination of ADC and bsAbs, has yet to be approved and several candidates are in the early stages of clinical development in this review. bsADCs technology helps increase the specificity of ADCs or the internalization and killing ability of bsAbs.
We also briefly discuss the application of click chemistry in the efficient development of ADCs and bsAbs as a conjugation strategy. The present review summarizes the ADCs, bsAbs, and bsADCs that have been approved for anti-cancer or currently in development. These strategies selectively deliver drugs to malignant tumor cells and can be used as therapeutic approaches for various types of cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。